CAR-macrophage: Breaking new ground in cellular immunotherapy
文献类型：期刊论文
| 作者 | Huang, Ting3,4; Bei, Chenqi3,4; Hu, Zhenhua4; Li, Yuanyuan1,2,3,4 |
| 刊名 | FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
 |
| 出版日期 | 2024-10-03 |
| 卷号 | 12页码:12 |
| 关键词 | macrophage chimeric antigen receptor CAR-M therapy tumor immunotherapy solid tumor |
| ISSN号 | 2296-634X |
| DOI | 10.3389/fcell.2024.1464218 |
| 通讯作者 | Hu, Zhenhua(baneyhua@163.com) ; Li, Yuanyuan(liyuanyuan@simm.ac.cn) |
| 英文摘要 | Chimeric Antigen Receptor (CAR) technology has revolutionized cellular immunotherapy, particularly with the success of CAR-T cells in treating hematologic malignancies. However, CAR-T cells have the limited efficacy of against solid tumors. To address these limitations, CAR-macrophages (CAR-Ms) leverage the innate properties of macrophages with the specificity and potency of CAR technology, offering a novel and promising approach to cancer immunotherapy. Preclinical studies have shown that CAR-Ms can effectively target and destroy tumor cells, even within challenging microenvironments, by exhibiting direct cytotoxicity and enhancing the recruitment and activation of other immune cells. Additionally, the favorable safety profile of macrophages and their persistence within solid tumors position CAR-Ms as potentially safer and more durable therapeutic options compared to CAR-T cells. This review explores recent advancements in CAR-Ms technology, including engineering strategies to optimize their anti-tumor efficacy and preclinical evidence supporting their use. We also discuss the challenges and future directions in developing CAR-Ms therapies, emphasizing their potential to revolutionize cellular immunotherapy. By harnessing the unique properties of macrophages, CAR-Ms offer a groundbreaking approach to overcoming the current limitations of CAR-T cell therapies, paving the way for more effective and sustainable cancer treatments. |
| WOS关键词 | TUMOR-ASSOCIATED MACROPHAGES ; DEATH APOPTOSIS ; CELLS ; CANCER ; POLARIZATION ; PHAGOCYTOSIS ; CHALLENGES ; EFFICACY ; DELIVERY ; THERAPY |
| 资助项目 | National Natural Science Foundation of China[82104252] ; National Natural Science Foundation of China[82473985] ; Shanghai Pujiang Program[21PJ1415600] ; Guangdong Basic and Applied Basic Research Foundation[2022A1515010491] ; Zhongshan Municipal Bureau of Science and Technology |
| WOS研究方向 | Cell Biology ; Developmental Biology |
| 语种 | 英语 |
| WOS记录号 | WOS:001332718900001 |
| 出版者 | FRONTIERS MEDIA SA |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/313820]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Hu, Zhenhua; Li, Yuanyuan |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China 3.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing, Peoples R China 4.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan, Peoples R China |
| 推荐引用方式 GB/T 7714 | Huang, Ting,Bei, Chenqi,Hu, Zhenhua,et al. CAR-macrophage: Breaking new ground in cellular immunotherapy[J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY,2024,12:12. |
| APA | Huang, Ting,Bei, Chenqi,Hu, Zhenhua,&Li, Yuanyuan.(2024).CAR-macrophage: Breaking new ground in cellular immunotherapy.FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY,12,12. |
| MLA | Huang, Ting,et al."CAR-macrophage: Breaking new ground in cellular immunotherapy".FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY 12(2024):12. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。